Web Analytics

3 Latest Announced Rounds

  • $43,000,000
    Series B

    1 Investors

    Hospital & Health Care
    Nov 14th, 2025
  • $3,500,000
    Seed
    IT Services and IT Consulting
    Nov 14th, 2025
  • Undisclosed Amount
    Series A

    1 Investors

    Software Development
    Nov 14th, 2025
$917.70M Raised in 40 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Merida Biosciences

start up
  • 10/04/2025
  • Series A
  • $121,000,000

Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.


Related People

Adam TownsendFounder

Adam Townsend United States - Greater Boston

N/A